SYLMAR, Calif.--(BUSINESS WIRE)--A study recently published online, and set to be issued in the February print edition of the peer-reviewed journal, Archives of Ophthalmology, demonstrated that the Argus® II Retinal Prosthesis System (Argus II – Manufactured by Second Sight Medical Products Inc.) enabled a majority of blind participants, implanted with the device, to identify the direction of moving objects better with the Argus II on than off. This journal article is the latest in a series of publications that shows that the Argus II restores some visual function to patients blinded by retinitis pigmentosa (RP), and that this function translates into real benefits in everyday life. Last month, an FDA Ophthalmic Devices Advisory Panel voted unanimously that the probable benefit of the Argus II outweighs the risks to health, clearing the way for regulatory approval in the US. The Argus II system has been approved for use in the European Economic Area and is on the market in several European countries since last year and remains the only approved retinal implant anywhere in the world.